Impact of Timed Carbohydrate Restriction on Liver Fat Regression in Non-Diabetic Adults With Obesity
Main Article Content
Abstract
Background: Hepatic steatosis is a common obesity-associated metabolic condition that may occur in non-diabetic adults and contribute to progressive hepatic and cardiometabolic risk. Dietary modification is central to management, but the effect of restricting carbohydrate intake to an earlier daily time window remains insufficiently defined. Objective: To evaluate whether timed carbohydrate restriction improves hepatic steatosis severity and metabolic indicators in non-diabetic adults with obesity. Methods: A parallel-group randomized controlled trial was conducted in Southern Punjab, Pakistan, from August 2025 to January 2026. Eighty non-diabetic adults aged 25–60 years with obesity and ultrasonography-confirmed hepatic steatosis were randomized to timed carbohydrate restriction or standard dietary advice. The intervention group consumed carbohydrate-containing foods only between 8:00 a.m. and 4:00 p.m. for 12 weeks, while the control group received conventional weight-management advice without carbohydrate-timing restriction. The primary outcome was change in ultrasound-graded hepatic steatosis severity. Secondary outcomes included body mass index, waist circumference, fasting insulin, HOMA-IR, and alanine aminotransferase. Results: Seventy-three participants completed follow-up assessment. Hepatic steatosis score decreased from 2.73 ± 0.61 to 1.38 ± 0.55 in the intervention group and from 2.69 ± 0.59 to 2.01 ± 0.63 in the control group. The between-group difference in mean change was -0.67, and the time-by-group interaction was significant (F=24.58, p<0.001). At 12 weeks, the intervention group also had lower BMI, waist circumference, fasting insulin, HOMA-IR, and alanine aminotransferase. Conclusion: Timed carbohydrate restriction was associated with greater 12-week improvement in hepatic steatosis and metabolic indicators among non-diabetic adults with obesity.
Article Details
Issue
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Marjot T, Tomlinson JW, Hodson L, Ray DW. Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD. Gastroenterology. 2023;72(8):1607-1619.
2. Papakonstantinou E, Oikonomou C, Nychas G, Dimitriadis GD. Effects of diet, lifestyle, chrononutrition and alternative dietary interventions on postprandial glycemia and insulin resistance. Nutrients. 2022;14(4):823.
3. Lackey H. Changes in dietary intake, macronutrients, diet quality, and hunger hormones after a 24-week diabetes education program featuring intermittent energy restriction or time-restricted eating. University of Kansas; 2025.
4. Perez-Diaz-del-Campo N, Castelnuovo G, Caviglia GP, Armandi A, Rosso C, Bugianesi E. Role of circadian clock on the pathogenesis and lifestyle management in non-alcoholic fatty liver disease. Nutrients. 2022;14(23):5053.
5. Reytor-González C, Cevallos-Fernández E, Jácome B, Simancas-Racines D. From meal to malfunction: exploring molecular pathways, biomarkers and interventions in postprandial cardiometabolic health. Front Cardiovasc Med. 2025;12:1655889.
6. Sharafifard F, Kazeminasab F, Ghanbari Rad M, Ghaedi K, Rosenkranz SK. The combined effects of high-intensity interval training and time-restricted feeding on the AKT/FOXO1/PEPCK pathway in diabetic rats. Sci Rep. 2025;15(1):13898.
7. Giannakogeorgou A, Roden M. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases. Aliment Pharmacol Ther. 2024;59 Suppl:S52-S75.
8. Jakubowicz D, Matz Y, Landau Z, Rosenblum RC, Twito O, Wainstein J, et al. Interaction between early meals, clock gene mRNA expression, and gut microbiome to regulate weight loss and glucose metabolism in obesity and type 2 diabetes. Nutrients. 2024;25(22):12355.
9. Wu L, Li S, Han F, Guo J, Zhang X, Xu L. Restoring circadian disrupted gut microbial metabolite rhythms with phytochemicals: a new avenue against metabolic disease. Front Microbiol. 2026;17:1801367.
10. Lv J, Zhao HP, Yu Y, Wang JH, Zhang XJ, Guo ZQ, et al. From gut microbial ecology to lipid homeostasis: decoding the role of gut microbiota in dyslipidemia pathogenesis and intervention. Int J Biol Macromol. 2025;31(30):108680.
11. Mukhopadhyay S, Mondal S. Metabolic syndrome: from mechanisms to interventions. Academic Press; 2023.
12. Tonin G, Eržen S, Mlinarič Z, Eržen DJ, Horvat S, Kunej T, et al. The genetic blueprint of obesity: from pathogenesis to novel therapies. Biology. 2025;26(12):e13978.
13. Flanagan A. Effects of timing of food intake and behaviours on daily rhythms of human metabolism. University of Surrey; 2023.
14. Zečević K, Popović N, Vuksanović Božarić A, Vukmirović M, Rizzo M, Muzurović E. Timing is important—management of metabolic syndrome according to the circadian rhythm. Biology. 2023;11(4):1171.
15. Alum EU. Circadian nutrition and obesity: timing as a nutritional strategy. J Health Popul Nutr. 2025;44(1):367.
16. Mentzelou M, Papadopoulou SK, Psara E, Voulgaridou G, Pavlidou E, Androutsos O, et al. Chrononutrition in the prevention and management of metabolic disorders: a literature review. Nutrients. 2024;16(5):722.
17. Reytor-González C, Simancas-Racines D, Román-Galeano NM, Annunziata G, Galasso M, Zambrano-Villacres R, et al. Chrononutrition and energy balance: how meal timing and circadian rhythms shape weight regulation and metabolic health. Nutrients. 2025;17(13):2135.
18. Ebeigbe OP. Regulation of hepatic lipid metabolism by calorie restriction and fasting: circadian clock and diet crosstalk. Cleveland State University; 2024.
19. Sheikh MY, Younus MF, Shergill A, Hasan MN. Diet and lifestyle interventions in metabolic dysfunction-associated fatty liver disease: a comprehensive review. Int J Mol Sci. 2025;26(19):9625.
20. Hao X, Song H, Su X, Li J, Ye Y, Wang C, et al. Prophylactic effects of nutrition, dietary strategies, exercise, lifestyle and environment on nonalcoholic fatty liver disease. Nutr Metab. 2025;57(1):2464223.